Medical Crossfire®: Leveraging the Lung Cancer Team in Stage III NSCLC With Immuno-Oncology Strategies
Registration and Lunch: 11:30 - 12:00
Program: 12:00 – 13:30
Conference Main Entrance:
Fira de Barcelona – Gran Via venue
Hall 8 – North Access
Medical Crossfire®: Leveraging the Lung Cancer Team in Stage III NSCLC With Immuno-Oncology Strategies will feature expert perspectives on the application of immunotherapy as a component of treatment with curative intent in patients with non–small cell lung cancer (NSCLC). This program will feature a multidisciplinary faculty including world-renowned experts in medical oncology, radiation oncology, and surgery. Current standards of care in patients with unresectable stage III NSCLC will be addressed, including the role of biomarkers and management of immune-related adverse events. Potential future roles for immunotherapy in stage I-III NSCLC will also be discussed, including incorporation into combined modality regimens and perioperative immunotherapy in patients with resectable disease. Throughout the program, expert Medical Crossfire® discussion panels will illustrate how experts address challenges in the implementation of immunotherapy for patients with locally advanced NSCLC. Be sure to join us for this exciting opportunity to improve your practice.
What You’ll Learn/Benefits of Attending
- See how top experts incorporate immunotherapeutic strategies in patients with unresectable stage III NSCLC
- Gain expert insights into the role of biomarkers for immunotherapy in patients with stage I-III NSCLC
- Develop strategies to address immune-related adverse events
- Learn about emerging strategies to apply immunotherapy in patients with resectable NSCLC
These activities are intended for an international audience of medical oncologists and other healthcare professionals interested in the latest advances in the treatment of patients with NSCLC. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with NSCLC are also invited to participate.
Upon successful completion of this activity, you should be better prepared to:
- Describe the scientific underpinnings of tumor immunology and the scientific rationale for immune checkpoint inhibition in the management of early stage and locally advanced NSCLC
- Apply clinical trial evidence to optimize the use of immune checkpoint inhibitors for the treatment of stage III NSCLC
- Evaluate evolving uses of biomarkers and how they have been investigated as methods to inform clinical decision-making in the care of patients with NSCLC
- Discuss methods to proactively identify and mitigate the impact of immune-related adverse events in stage III NSCLC
Professor of Medicine
Director, Thoracic Oncology
Co-Director, Cancer Immunotherapy Program
Price Chair, Clinical Translational Research
Columbia University Medical Center
New York, New York, USA
Registration2 Ways to Register
- Online: click here.
- Phone: Please call +1 (888) 949-0045 or +1 (609) 378-3701.
2 Clarke Drive
Cranbury, New Jersey 08512
Registration Fee - Free
For registration assistance, please email firstname.lastname@example.org, or call +1 (888) 949-0045 or +1 (609) 378-3701.
Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call +1 (609) 378-3701.
Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited. This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.
By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.
Meeting information is accurate at the time of posting.
PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.
This program was approved by the IASLC 2019 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2019 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.
You must be logged in to PER to register for this meeting
Or Register for PER now